| Identification | Back Directory | [Name]
L-Threoninamide, N-[2-[4-(2-hydroxyethyl)-1-piperazinyl]acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-(2S)-2-aminobutanoyl-L-cysteinyl-, cyclic (2→7)-disulfide | [CAS]
182153-96-4 | [Synonyms]
BDBM85051
BIM-23190
L-Threoninamide, N-[2-[4-(2-hydroxyethyl)-1-piperazinyl]acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-(2S)-2-aminobutanoyl-L-cysteinyl-, cyclic (2→7)-disulfide | [Molecular Formula]
C57H79N13O12S2 | [MDL Number]
MFCD34471157 | [MOL File]
182153-96-4.mol | [Molecular Weight]
1202.46 |
| Hazard Information | Back Directory | [Uses]
BIM-23190, a somatostatin analog, a selective SSTR2 and SSTR5 agonist, exhibits Ki values of 0.34 nM and 11.1 nM for SSTR2 and SSTR5, respectively. BIM-23190 can be used in the study for cancer and acromegaly[1][3]. | [in vivo]
BIM-23190 (50 μg/mouse, twice a day) exhibits significant anti-tumor (C6 glioma) activity[2].
| Animal Model: | Male athymic nude (nu/nu) mice, 5-6 wk old (C6 glioma)[2]. | | Dosage: | 50 μg/mouse | | Administration: | Injected twice a day for 19 days. | | Result: | Significantly reduced the tumor growth rate. |
| [IC 50]
SSTR2; SSTR5 | [References]
[1] I Shimon, et al. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest. 1997 Nov 1;100(9):2386-92. DOI:10.1172/JCI119779
[2] Federica Barbieri, et al. Differential efficacy of SSTR1, -2, and -5 agonists in the inhibition of C6 glioma growth in nude mice. Am J Physiol Endocrinol Metab. 2009 Nov;297(5):E1078-88. DOI:10.1152/ajpendo.00292.2009
[3] T J Gillespie, et al. Novel somatostatin analogs for the treatment of acromegaly and cancer exhibit improved in vivo stability and distribution. J Pharmacol Exp Ther. 1998 Apr;285(1):95-104. PMID:9535998 |
|
|